UKRI awards three projects £25m for vaccine development
The projects will support the development of new and longer-lasting vaccines
Read More
Tag: Vaccine development
Further clinical trial planned for Valneva’s COVID-19 vaccine candidate
Trial will aim to generate additional safety and immunogenicity data
Read More
BioNTech to develop a mRNA-based malaria vaccine
Clinical trial for first vaccine candidate is planned for the end of 2022
Read More
AstraZeneca’s COVID-19 vaccine shows 79% efficacy in US trial
Jab was also found to have 100% efficacy at preventing severe disease and hospitalisation
Read More
Modified COVID-19 vaccines can avoid ‘lengthy’ clinical studies, says MHRA
UK’s regulatory authority will fast-track jabs modified to new variants
Read More
ConserV Bio partners with eTheRNA on mRNA vaccine development
Collaboration will focus on vaccines for infectious diseases
Read More
ConserV Bioscience to develop ‘broad-spectrum’ coronavirus vaccine
UK biotech company will collaborate with Lawrence Livermore National Laboratory
Read More
Valneva partners with Oxford Immunotec on T cell analysis for COVID-19 vaccine
Oxford Immunotec will perform T cell testing on participants receiving Valneva’s vaccine candidate
Read More
Sanofi, GSK face COVID-19 vaccine trial delay
Potential availability of vaccine now delayed to the end of 2021
Read More
Valneva fast-tracks paediatric development of Lyme disease vaccine
Company plans phase II study launch in first quarter of 2021
Read More
GSK launches late-stage study of RSV vaccine in pregnant mothers
Shot will be evaluated in pregnant mothers and their newborn infants
Read More
UK strikes deal for five million doses of Moderna’s COVID-19 vaccine
Initial interim data suggests vaccine is 94.5% effective
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
